Qiagen & Protedyne target ultra-high volume diagnostics
This article was originally published in Clinica
Qiagen, a leading supplier of nucleic acid and protein separation, purification and handling technology, has teamed up with Protedyne, a developer of high-throughput industrial robotic platforms, to target the market for ultra-high throughput systems - processing more than 600 samples per day - for molecular diagnostics and pharmaceutical research. As part of the deal, Venlo, the Netherlands-based Qiagen will invest $2m in Protedyne, of Windsor, Connecticut, and receive exclusive access to Protedyne's automation technologies for filter-based nucleic acid sample preparation.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.